Loading…
Reported covered position: Intern, Rep. Kendra Horn (2019)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Nuclear Medicine Clarification Act of 2025
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to the Nuclear Regulatory Commission's preliminary proposed rule titled, "Reporting Nuclear Medicine Injection Extravasations as Medical Events" (10 CFR 35). Issues related to the Nuclear Medicine Clarification Act of 2025 (H.R. 2541).
Treat and Reduce Obesity Act of 2025
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
NEW YORK BLOOD CENTER ENTERPRISES via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · third_quarter · Q3
Issues related to HRSA's regulation of cord blood storage and the Stem Cell Therapeutic and Research Reauthorization Act (H.R. 5160/S. 4109).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · third_quarter · Q3
Source: Senate LDA
| NOVO NORDISK A S |
| 4 |
| 2024–2025 |
| NEURALINK CORP. | 3 | 2026 |
| SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2 | 2026 |
| Spyre Therapeutics, Inc. | 1 | 2026 |
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).
Treat and Reduce Obesity Act of 2025
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).
Treat and Reduce Obesity Act of 2025
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).
Stem Cell Therapeutic and Research Reauthorization Act of 2025
Client: NEW YORK BLOOD CENTER ENTERPRISES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to HRSA's regulation of cord blood storage and the Stem Cell Therapeutic and Research Reauthorization Act (H.R. 5160/S. 4109).
Stem Cell Therapeutic and Research Reauthorization Act of 2025
Client: NEW YORK BLOOD CENTER ENTERPRISES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to HRSA's regulation of cord blood storage and the Stem Cell Therapeutic and Research Reauthorization Act (HR5160/S4109).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to medical research funding. Issues related to theranostics report language in House Report 119-271 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304)], and Senate Report 119-55 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (S. 2587)]. Issues related to theranostics report language in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)]. Issues related to theranostics research within the Congressionally Directed Medical Research Programs (CDMRP).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to medical research funding. Issues related to theranostics report language in House Report 119-271 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304)], and Senate Report 119-55 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (S. 2587)]. Issues related to theranostics report language in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)]. Issues related to theranostics research within the Congressionally Directed Medical Research Programs (CDMRP).
Treat and Reduce Obesity Act of 2025
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).
Treat and Reduce Obesity Act of 2025
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).
Treat and Reduce Obesity Act of 2025
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to medical research funding. Issues related to theranostics report language in House Report 119-271 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304)], and Senate Report 119-55 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (S. 2587)]. Issues related to theranostics report language in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)]. Issues related to theranostics research within the Congressionally Directed Medical Research Programs (CDMRP).
Stem Cell Therapeutic and Research Reauthorization Act of 2026
Client: NEW YORK BLOOD CENTER ENTERPRISES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to HRSA's regulation of cord blood storage and the Stem Cell Therapeutic and Research Reauthorization Act (HR5160/S4109).
Stem Cell Therapeutic and Research Reauthorization Act of 2026
Client: NEW YORK BLOOD CENTER ENTERPRISES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to HRSA's regulation of cord blood storage and the Stem Cell Therapeutic and Research Reauthorization Act (H.R. 5160/S. 4109).
Treat and Reduce Obesity Act of 2025
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).
Treat and Reduce Obesity Act of 2025
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).
Treat and Reduce Obesity Act of 2025
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).
Treat and Reduce Obesity Act of 2025
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407, 118th Congress).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407, 118th Congress).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407, 118th Congress).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407, 118th Congress).
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Legislation related to antikickback exclusions for travel and lodging arrangements between manufacturers of drugs and patients
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Legislation related to antikickback exclusions for travel and lodging arrangements between manufacturers of drugs and patients
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407, 118th Congress).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407).
Creating Hope Reauthorization Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Legislation related to antikickback exclusions for travel and lodging arrangements between manufacturers of drugs and patients
Creating Hope Reauthorization Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Creating Hope Reauthorization Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Legislation related to antikickback exclusions for travel and lodging arrangements between manufacturers of drugs and patients
Creating Hope Reauthorization Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Creating Hope Reauthorization Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Creating Hope Reauthorization Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Patient Access Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Patient Access Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Patient Access Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Patient Access Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407, 118th Congress).
Creating Hope Reauthorization Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Creating Hope Reauthorization Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Legislation related to antikickback exclusions for travel and lodging arrangements between manufacturers of drugs and patients
Creating Hope Reauthorization Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Legislation related to antikickback exclusions for travel and lodging arrangements between manufacturers of drugs and patients
Creating Hope Reauthorization Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Creating Hope Reauthorization Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Creating Hope Reauthorization Act of 2024
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Medicaid VBPs for Patients Act
Client: GENETIX BIOTHERAPEUTICS, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407).
Third Reconstruction: Fully addressing poverty and low wages from the bottom up.
Client: FEDERATION OF PROTESTANT WELFARE AGENCIES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Raising awareness for the need to revise the federal poverty measure to reflect cost of living changes. Conveyed support for H.Res. 532 "Third Reconstruction: Fully addressing poverty and low wages from the bottom up."
Third Reconstruction: Fully addressing poverty and low wages from the bottom up.
Client: COMMUNITY SERVICE SOCIETY OF NEW YORK · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Raising awareness for the need to revise the federal poverty measure to reflect cost of living changes. Conveyed support for H.Res. 532 "Third Reconstruction: Fully addressing poverty and low wages from the bottom up."
Third Reconstruction: Fully addressing poverty and low wages from the bottom up.
Client: COMMUNITY SERVICE SOCIETY OF NEW YORK · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Raising awareness for the need to revise the federal poverty measure to reflect cost of living changes. Conveyed support for H.Res. 532 "Third Reconstruction: Fully addressing poverty and low wages from the bottom up."
Third Reconstruction: Fully addressing poverty and low wages from the bottom up.
Client: FEDERATION OF PROTESTANT WELFARE AGENCIES · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Raising awareness for the need to revise the federal poverty measure to reflect cost of living changes. Conveyed support for H.Res. 532 "Third Reconstruction: Fully addressing poverty and low wages from the bottom up."
Treat and Reduce Obesity Act of 2023
Client: NOVO NORDISK, INC. · Firm: ARNOLD & PORTER KAYE SCHOLER LLP
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407).
Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability. Issues related to general compounding.
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).
Issues related to general compounding.
Issues related to general compounding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · third_quarter · Q3
Issues and legislation related to access to gene therapies and treatment of rare diseases.
Issues and legislation related to access to gene therapies and treatment of rare diseases.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NEURALINK CORP. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · third_quarter · Q3
Issues related to access to medical devices, including neurotechnology/brain-computer interface products.
Issues related to Medicare coverage and reimbursement pathways for breakthrough medical devices.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, White House Office
NEURALINK CORP. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · second_quarter · Q2
Issues related to access to medical devices, including neurotechnology/brain-computer interface products.
Issues related to Medicare coverage and reimbursement pathways for breakthrough medical devices.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · second_quarter · Q2
Issues related to theranostics research within the Congressionally Directed Medical Research Programs (CDMRP).
Issues related to physician payment reform. Issues related to CMS reimbursement for radiopharmaceuticals.
Issues related to medical research funding. Issues related to theranostics report language in House Report 119-271 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (H.R. 5304)], and Senate Report 119-55 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 (S. 2587)]. Issues related to theranostics report language in House Report 119-696 [which accompanies the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260)]. Issues related to theranostics research within the Congressionally Directed Medical Research Programs (CDMRP).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEW YORK BLOOD CENTER ENTERPRISES via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · second_quarter · Q2
Issues related to HRSA's regulation of cord blood storage and the Stem Cell Therapeutic and Research Reauthorization Act (HR5160/S4109).
Filing targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · second_quarter · Q2
Issues related to general compounding.
Issues related to general compounding.
Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability. Issues related to general compounding.
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · second_quarter · Q2
Issues and legislation related to access to gene therapies and treatment of rare diseases.
Issues and legislation related to access to gene therapies and treatment of rare diseases.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NEURALINK CORP. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · second_quarter · RR
Issues related to the development and commercialization of brain-computer interfaces.
SPYRE THERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · first_quarter · Q1
Issues related to monoclonal antibody products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · first_quarter · Q1
Issues related to theranostics research within the Congressionally Directed Medical Research Programs (CDMRP).
Issues related to tariffs on nuclear medicines and radiopharmaceuticals.
Issues related to the Nuclear Regulatory Commission's preliminary proposed rule titled, "Reporting Nuclear Medicine Injection Extravasations as Medical Events" (10 CFR 35). Issues related to the Nuclear Medicine Clarification Act of 2025 (H.R. 2541).
NEW YORK BLOOD CENTER ENTERPRISES via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · first_quarter · Q1
Issues related to HRSA's regulation of cord blood storage.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · first_quarter · Q1
Issues related to general compounding.
Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability. Issues related to general compounding.
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · first_quarter · Q1
Issues and legislation related to access to gene therapies and treatment of rare diseases.
Issues and legislation related to access to gene therapies and treatment of rare diseases.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NEW YORK BLOOD CENTER ENTERPRISES via ARNOLD & PORTER KAYE SCHOLER LLP
2026 · first_quarter · RR
Issues related to cord blood storage.
FEDERATION OF PROTESTANT WELFARE AGENCIES via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · fourth_quarter · Q4
Issues related to measuring the cost of living for American households.
Issues related to measuring American household resources to meet the cost of living.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · fourth_quarter · Q4
Issues related to general compounding.
Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability. Issues related to general compounding.
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · fourth_quarter · Q4
Issues and legislation related to access to gene therapies and treatment of rare diseases.
Issues and legislation related to access to gene therapies and treatment of rare diseases.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FEDERATION OF PROTESTANT WELFARE AGENCIES via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · third_quarter · Q3
Issues related to measuring the cost of living for American households.
Issues related to measuring American household resources to meet the cost of living.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · third_quarter · Q3
Issues related to the 340B Program. Issues related to general compounding.
Issues related to the 340B program. Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability. Issues related to general compounding.
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · third_quarter · Q3
Issues and legislation related to access to gene therapies and treatment of rare diseases.
Issues and legislation related to access to gene therapies and treatment of rare diseases.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · second_quarter · Q2
Issues related to pharmacy benefit managers (PBMs). Issues related to the 340B Program. Issues related to general compounding.
Issues related to pharmacy benefit managers (PBMs) and the 340B program. Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability. Issues related to general compounding.
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407, 118th Congress).
PERRIGO COMPANY PLC via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · second_quarter · Q2
Issues related to the manufacturing of infant formula.
Issues related to the manufacturing of infant formula.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
FEDERATION OF PROTESTANT WELFARE AGENCIES via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · second_quarter · Q2
Issues related to measuring the cost of living for American households.
Issues related to measuring American household resources to meet the cost of living.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · second_quarter · Q2
Issues and legislation related to access to gene therapies and treatment of rare diseases.
Issues and legislation related to access to gene therapies and treatment of rare diseases.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PERRIGO COMPANY PLC via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · first_quarter · Q1
Issues related to over-the-counter birth control and the manufacturing of infant formula.
Issues related to the manufacturing of infant formula.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · first_quarter · Q1
Issues related to pharmacy benefit managers (PBMs) and the 340B Program.
Issues related to pharmacy benefit managers (PBMs) and the 340B program. Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability.
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407, 118th Congress).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FEDERATION OF PROTESTANT WELFARE AGENCIES via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · first_quarter · Q1
Issues related to measuring the cost of living for American households.
Issues related to measuring American household resources to meet the cost of living
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK A/S via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · first_quarter · Q1
Issues related to manufacturing capacity and supply chain resiliency.
Issues related to manufacturing capacity and supply chain resiliency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · first_quarter · Q1
Issues and legislation related to access to gene therapies and treatment of rare diseases.
Issues and legislation related to access to gene therapies and treatment of rare diseases.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COMMUNITY SERVICE SOCIETY OF NEW YORK via ARNOLD & PORTER KAYE SCHOLER LLP
2025 · first_quarter · 1T
Issues related to measuring the cost of living for American households.
Issues related to measuring American household resources to meet the cost of living.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FEDERATION OF PROTESTANT WELFARE AGENCIES via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · fourth_quarter · Q4
Issues related to raising awareness for the need to revise the federal poverty measure to reflect cost of living changes.
Issues related to raising awareness for the need to revise the federal poverty measure to reflect cost of living changes.
Filing targets: Council of Economic Advisers (CEA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Office of Management & Budget (OMB), SENATE
COMMUNITY SERVICE SOCIETY OF NEW YORK via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · fourth_quarter · Q4
Issues related to raising awareness for the need to revise the federal poverty measure to reflect cost of living changes.
Issues related to raising awareness for the need to revise the federal poverty measure to reflect cost of living changes.
Filing targets: Council of Economic Advisers (CEA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Office of Management & Budget (OMB), SENATE
PERRIGO COMPANY PLC via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · fourth_quarter · 4A
Issues related to the manufacturing of infant formula.
Issues related to over-the-counter birth control and the manufacturing of infant formula.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PERRIGO COMPANY PLC via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · fourth_quarter · Q4
Issues related to the manufacturing of infant formula.
Issues related to over-the-counter birth control and the manufacturing of infant formula.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · fourth_quarter · Q4
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
NOVO NORDISK A/S via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · fourth_quarter · Q4
Issues related to manufacturing capacity and supply chain resiliency.
Issues related to manufacturing capacity and supply chain resiliency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · fourth_quarter · Q4
Issues related to pharmacy benefit managers (PBMs) and the 340B Program.
Issues related to pharmacy benefit managers (PBMs) and the 340B program. Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability.
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407, 118th Congress).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · third_quarter · Q3
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Patient Access Act (H.R. 9184)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · third_quarter · Q3
Issues related to pharmacy benefit managers (PBMs) and the 340B Program.
Issues related to pharmacy benefit managers (PBMs) and the 340B program. Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability.
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
NOVO NORDISK A/S via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · third_quarter · Q3
Issues related to manufacturing capacity and supply chain resiliency.
Issues related to manufacturing capacity and supply chain resiliency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FEDERATION OF PROTESTANT WELFARE AGENCIES via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · third_quarter · Q3
Issues related to raising awareness for the need to revise the federal poverty measure to reflect cost of living changes.
Issues related to raising awareness for the need to revise the federal poverty measure to reflect cost of living changes.
Filing targets: Council of Economic Advisers (CEA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Office of Management & Budget (OMB), SENATE
COMMUNITY SERVICE SOCIETY OF NEW YORK via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · third_quarter · Q3
Issues related to raising awareness for the need to revise the federal poverty measure to reflect cost of living changes.
Issues related to raising awareness for the need to revise the federal poverty measure to reflect cost of living changes.
Filing targets: Council of Economic Advisers (CEA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Office of Management & Budget (OMB), SENATE
NOVO NORDISK A/S via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · second_quarter · Q2
Issues related to manufacturing capacity and supply chain resiliency.
Issues related to manufacturing capacity and supply chain resiliency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PERRIGO COMPANY PLC via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · second_quarter · Q2
Issues related to the manufacturing of infant formula.
Issues related to the manufacturing of infant formula and issues related to over-the-counter birth control.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · second_quarter · Q2
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Legislation related to antikickback exclusions for travel and lodging arrangements between manufacturers of drugs and patients
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666); Creating Hope Reauthorization Act (H.R. 7384 / S. 4583); Legislation related to antikickback exclusions for travel and lodging arrangements between manufacturers of drugs and patients
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · second_quarter · Q2
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407).
Issues related to pharmacy benefit managers and the 340B program. Issues related to the clinical and overall benefit of anti-obesity medications.
Issues related to pharmacy benefit managers and the 340B Program.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
FEDERATION OF PROTESTANT WELFARE AGENCIES via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · second_quarter · Q2
Issues related to raising awareness for the need to revise the federal poverty measure to reflect cost of living changes.
Issues related to raising awareness for the need to revise the federal poverty measure to reflect cost of living changes.
Filing targets: Council of Economic Advisers (CEA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Office of Management & Budget (OMB), SENATE
COMMUNITY SERVICE SOCIETY OF NEW YORK via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · second_quarter · Q2
Issues related to raising awareness for the need to revise the federal poverty measure to reflect cost of living changes.
Issues related to raising awareness for the need to revise the federal poverty measure to reflect cost of living changes.
Filing targets: Council of Economic Advisers (CEA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Office of Management & Budget (OMB), SENATE
PERRIGO COMPANY PLC via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · first_quarter · Q1
Issues related to the manufacturing of infant formula and issues related to over-the-counter birth control.
Issues related to the manufacturing of infant formula.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · first_quarter · Q1
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · first_quarter · Q1
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407).
Issues related to pharmacy benefit managers and the 340B program. Issues related to the clinical and overall benefit of anti-obesity medications.
Issues related to pharmacy benefit managers and the 340B Program.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
FEDERATION OF PROTESTANT WELFARE AGENCIES via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · first_quarter · Q1
Raising awareness for the need to revise the federal poverty measure to reflect cost of living changes.
Raising awareness for the need to revise the federal poverty measure to reflect cost of living changes.
Filing targets: Council of Economic Advisers (CEA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Office of Management & Budget (OMB), SENATE
COMMUNITY SERVICE SOCIETY OF NEW YORK via ARNOLD & PORTER KAYE SCHOLER LLP
2024 · first_quarter · Q1
Raising awareness for the need to revise the federal poverty measure to reflect cost of living changes.
Raising awareness for the need to revise the federal poverty measure to reflect cost of living changes.
Filing targets: Council of Economic Advisers (CEA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Office of Management & Budget (OMB), SENATE
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · fourth_quarter · Q4
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PERRIGO COMPANY PLC via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · fourth_quarter · Q4
Issues related to the manufacturing of infant formula.
Issues related to the manufacturing of infant formula and issues related to over-the-counter birth control.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · fourth_quarter · Q4
Issues related to pharmacy benefit managers and the 340B Program.
Issues related to pharmacy benefit managers and the 340B program. Issues related to the clinical and overall benefit of anti-obesity medications.
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FEDERATION OF PROTESTANT WELFARE AGENCIES via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · fourth_quarter · Q4
Raising awareness for the need to revise the federal poverty measure to reflect cost of living changes.
Raising awareness for the need to revise the federal poverty measure to reflect cost of living changes.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE
COMMUNITY SERVICE SOCIETY OF NEW YORK via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · fourth_quarter · Q4
Raising awareness for the need to revise the federal poverty measure to reflect cost of living changes.
Raising awareness for the need to revise the federal poverty measure to reflect cost of living changes.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE
PERRIGO COMPANY PLC via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · third_quarter · Q3
Issues related to the manufacturing of infant formula.
Issues related to the manufacturing of infant formula and issues related to over-the-counter birth control.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · third_quarter · Q3
Issues related to pharmacy benefit managers and the 340B program. Issues related to the clinical and overall benefit of anti-obesity medications.
Issues related to CMS coverage of anti-obesity medications.
Issues related to pharmacy benefit managers and the 340B Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FEDERATION OF PROTESTANT WELFARE AGENCIES via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · third_quarter · Q3
Raising awareness for the need to revise the federal poverty measure to reflect cost of living changes. Conveyed support for H.Res. 532 "Third Reconstruction: Fully addressing poverty and low wages from the bottom up."
Raising awareness for the need to revise the federal poverty measure to reflect cost of living changes. Conveyed support for H.Res. 532 "Third Reconstruction: Fully addressing poverty and low wages from the bottom up."
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Office of Management & Budget (OMB), SENATE
COMMUNITY SERVICE SOCIETY OF NEW YORK via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · third_quarter · Q3
Raising awareness for the need to revise the federal poverty measure to reflect cost of living changes. Conveyed support for H.Res. 532 "Third Reconstruction: Fully addressing poverty and low wages from the bottom up."
Raising awareness for the need to revise the federal poverty measure to reflect cost of living changes. Conveyed support for H.Res. 532 "Third Reconstruction: Fully addressing poverty and low wages from the bottom up."
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Office of Management & Budget (OMB), SENATE
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · third_quarter · Q3
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · second_quarter · Q2
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PERRIGO COMPANY PLC via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · second_quarter · Q2
Issues related to the manufacturing of infant formula and issues related to over-the-counter birth control.
Issues related to the manufacturing of infant formula.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · second_quarter · Q2
Issues related to pharmacy benefit managers and the 340B program.
Issues related to pharmacy benefit managers and the 340B Program.
Issues related to CMS coverage of anti-obesity medications.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FEDERATION OF PROTESTANT WELFARE AGENCIES via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · second_quarter · Q2
Raising awareness for the need to revise the federal poverty measure to reflect cost of living changes.
Raising awareness for the need to revise the federal poverty measure to reflect cost of living changes.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COMMUNITY SERVICE SOCIETY OF NEW YORK via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · second_quarter · Q2
Raising awareness for the need to revise the federal poverty measure to reflect cost of living changes.
Raising awareness for the need to revise the federal poverty measure to reflect cost of living changes.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENETIX BIOTHERAPEUTICS, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · second_quarter · RR
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
Issues and legislation related to access to gene therapies and treatment of rare diseases; the Medicaid VBPs for Patients (MVP) Act (H.R. 2666).
NOVO NORDISK, INC. via ARNOLD & PORTER KAYE SCHOLER LLP
2023 · second_quarter · RR
Issues and legislation related to (1) Medicare coverage of anti-obesity medications (AOMs), and (2) the 340B drug pricing program.
Issues and legislation related to (1) Medicare coverage of anti-obesity medications (AOMs), and (2) the 340B drug pricing program.
Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to medical research funding. Issues related to theranostics report language in House Report 119-271 and Senate Report 119-55. Issues related to theranostics research within the Congressionally Directed Medical Research Programs (CDMRP).
Issues related to physician payment reform. Issues related to CMS reimbursement for radiopharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to general compounding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to general compounding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to general compounding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to general compounding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE